Anagliptin decreases FABP4 concentration independent of change in hemoglobin A1c or LDL-C in patients with type 2 diabetes mellitus at a high risk for cardiovascular events who are on statin therapy. The gene discussed is FABP4; the disease is type 2 diabetes mellitus.